Probe group for detecting non-small cell lung cancer MRD and application thereof
By designing a probe set for non-small cell lung cancer, monitoring tumor evolution and new drug-resistant mutations, the problem of MRD detection in the prior art is solved, and the drug-resistant mutations caused by tumor clonal evolution is achieved, achieving high sensitivity and Specific MRD monitoring effect.
Patent Information
- Application Number
- CN202411173634.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-23
AI Technical Summary
The prior art is difficult to effectively monitor new drug-resistant mutations caused by tumor clonal evolution after patients with non-small cell lung cancer after radical treatment, affecting the accuracy of MRD detection and predicting recurrence risk.
Provide a probe set for detecting tiny residual lesions of non-small cell lung cancer, including probes such as EGFR, KRAS, ERBB2, BRAF, MET, ALK, TP53, PIK3CA, CTNNB1, SMAD4, CDKN2A or NFE2L2, through specific nucleotide sequence design improves capture efficiency and depth, and monitors tumor evolution and new drug-resistant mutations.
It has achieved high sensitivity and specificity for MRD monitoring of non-small cell lung cancer, which can overcome the temporal and spatio-temporal heterogeneity of tumors to a certain extent, improve capture efficiency and stability, meet clinical detection requirements, and significantly improve resistance to new drugs Mutation detection capability.
Smart Images

Figure BDA0005010764510000071 
Figure BDA0005010764510000082 
Figure BDA0005010764510000091
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of nucleic acid sequencing. Specifically, the present invention relates to a probe set for detecting MRD in non-small cell lung cancer and its application. Background Art
[0002] Minimal residual disease (MRD) refers to the situation in which a cancer patient achieves complete radiographic remission after radical treatment, but there are still residual tumor cells or tiny lesions in the body that cannot be detected by imaging methods. This is a latent stage of tumor progression. The number of residual tumor cells may be very small and will not cause any signs or symptoms for the time being, but may lead to future tumor progression or recurrence and metastasis. Circulating tumor DNA (ctDNA) sequencing can detect this molecular abnormality and is used for prognosis assessment, recurrence monitoring, efficacy evaluation, and auxiliary treatment decision-making, which can provide an important reference for clinical treatment decisions.
[0003] The MRD status based on ctDNA detection is closely related to the risk of recurrence of non-small cell lung cancer. For patients with early lung cancer who undergo radical surgery, ctDNA positivity can predict recurrence earlier than traditional imaging. Patients with MRD-positive non-small cell lung cancer have a higher risk of recurrence, and patients with MRD-positive can benefit from adjuvant therapy. In recent years, some domestic and foreign cancer diagnosis and treatment guidelines and expert consensus have gradually used ctDNA as a prognostic biomarker. my country's "Expert Consensus on Molecular Residual Lesions in Non-Small Cell Lung Cancer" recommends that "after radical resection of early non-small cell lung cancer patients, MRD positivity indicates a high risk of recurrence and requires close follow-up management. It is recommended that MRD testing be performed every 3 to 6 months."
[0004] The personalized customized MRD probes in the existing technology cannot effectively monitor the emerging drug-resistant mutations caused by the selection pressure caused by drug treatment and other factors that lead to the clonal evolution of tumors. How to effectively monitor the emerging drug-resistant mutations caused by clonal evolution is a challenge faced by MRD testing. Summary of the invention
[0005] In order to solve at least one of the above problems, the present disclosure provides a gene marker, a probe set, a screening method, a detection method and its application for detecting micro-residual lesions of non-small cell lung cancer. The probe set provided by the present disclosure has excellent capture efficiency and depth coefficient, and good probe uniformity. The probe set provided by the present disclosure can be used to detect new drug-resistant mutations caused by tumor evolution and clonal evolution in micro-residual lesions, and can also improve capture efficiency and stabilize the experimental system.
[0006] According to one aspect of the present disclosure, a gene marker for detecting minimal residual lesions of non-small cell lung cancer is provided, wherein the marker comprises any one or more of the following genes: EGFR, KRAS, ERBB2, BRAF, MET, ALK, TP53, PIK3CA, CTNNB1, SMAD4, CDKN2A or NFE2L2.
[0007] In some embodiments, the gene markers include any one or more of the following regions: exons 18, 19, 20, 21 of EGFR, exons 2, 3, 4 of KRAS, exon 20 of ERBB2, exons 11, 15 of BRAF, intron 13, exon 14 of MET, exon 23 of ALK, exons 4-10 of TP53, exons 10, 21 of PIK3CA, exon 3 of CTNNB1, exon 9 of SMAD4, exons 1, 2 of CDKN2A and exon 2 of NFE2L2.
[0008] In some embodiments, the probe set is used to detect the gene markers disclosed herein.
[0009] In some embodiments, the probe set has a nucleotide sequence as shown in any one or more of SEQ ID NOs: 1 to 57, or a nucleotide sequence having at least 85% sequence identity thereto.
[0010] In some embodiments, the probe set includes any one or more combinations of the following:
[0011] A probe for detecting the ALK gene: having a nucleotide sequence as shown in SEQ ID NO: 1 and / or 2, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0012] A probe for detecting the NFE2L2 gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 3 to 5, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0013] A probe for detecting the CTNNB1 gene: having a nucleotide sequence as shown in SEQ ID NO: 6 and / or 7, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0014] A probe for detecting the PIK3CA gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 8 to 12, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0015] A probe for detecting the EGFR gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 13 to 20, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0016] A probe for detecting the MET gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 21 to 23, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0017] A probe for detecting the BRAF gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 24 to 27, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0018] A probe for detecting the CDKN2A gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 28 to 32, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0019] A probe for detecting the KRAS gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 33 to 38, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0020] A probe for detecting the TP53 gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 39 to 53, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0021] A probe for detecting the ERBB2 gene: having a nucleotide sequence as shown in SEQ ID NO: 54 and / or 55, or a nucleotide sequence having at least 85% sequence identity thereto; and / or
[0022] The probe for detecting the SMAD4 gene has a nucleotide sequence as shown in SEQ ID NO: 56 and / or 57, or a nucleotide sequence having at least 85% sequence identity thereto.
[0023] According to another aspect of the present disclosure, a kit for detecting minimal residual lesions of non-small cell lung cancer is provided, the kit comprising the probe set.
[0024] According to another aspect of the present disclosure, a method for detecting minimal residual lesions of non-small cell lung cancer using the probe group and / or the kit of the present disclosure is provided, and the method comprises using the probe group and / or the kit to detect minimal residual lesions of non-small cell lung cancer.
[0025] According to another aspect of the present disclosure, provided is a use of the gene markers and / or probe sets described in the present disclosure in preparing a kit for detecting minimal residual lesions of non-small cell lung cancer.
[0026] In some embodiments, the kit is used for detecting cell, tissue or body fluid samples.
[0027] In some embodiments, the cell sample comprises a lung cancer cell suspension sample.
[0028] In some embodiments, the body fluid sample includes: saliva, whole blood, serum, plasma, milk, urine, lumbar or ventricular CSF, bile, lymph, prostatic fluid, semen, sputum, feces, tears, tumor cells, alveolar lavage fluid, sputum, pus, nasopharyngeal swab, oral swab, cerebrospinal fluid, pleural effusion, amniotic fluid, peritoneal fluid, aqueous humor, vitreous humor, vaginal discharge and their processed products.
[0029] In some embodiments, the tissue sample includes lung cancer tissue, paraffin sections, and processed materials thereof.
[0030] Beneficial effects:
[0031] The probe set provided in the present disclosure includes drug mutations and high-frequency mutations with high evidence levels in non-small cell lung cancer, and can be used alone or in combination with other probe sets for non-small cell lung cancer MRD monitoring, with good sensitivity and specificity. The non-small cell lung cancer cancer-specific probe set disclosed in the present disclosure can play a role in monitoring tumor evolution and emerging drug-resistant mutations, and can overcome the temporal and spatial heterogeneity of tumors to a certain extent, while also improving capture efficiency and stabilizing the experimental system.
[0032] Verified by clinical samples, the probe set of the present invention has excellent capture efficiency and depth coefficient, good probe uniformity, and can meet clinical detection requirements. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 Shown are the capture efficiency test results of the non-small cell lung cancer specific probe set.
[0034] Figure 2 The results of the non-small cell lung cancer specific probe set ≥ 0.2 times the average depth percentage test are shown.
[0035] Figure 3 The results of the non-small cell lung cancer specific probe set ≥ 0.5 times the average depth percentage test are shown.
[0036] Figure 4 The results of the depth factor test of the non-small cell lung cancer specific probe set are shown.
[0037] Figure 5The figure shows the coverage results of the non-small cell lung cancer specific probe set for non-small cell lung cancer patient tissue mutations.
[0038] Figure 6 The figure shows the test results of the accuracy of MRD detection of non-small cell lung cancer by superimposing the non-small cell lung cancer specific probe group and the patient specific probe group. DETAILED DESCRIPTION
[0039] The present disclosure provides a personalized MRD probe group specific to non-small cell lung cancer, covering mutations with drug significance, as well as non-small cell lung cancer-specific high-frequency mutations screened out based on sequencing data of 12,854 cases of non-small cell lung cancer reported in TCGA, COSMIC and literature, for MRD monitoring of non-small cell lung cancer. This probe group covers a total of 12 non-small cell lung cancer-related drug or high-frequency genes: EGFR, KRAS, ERBB2, BRAF, MET, BRAF, ALK, TP53, PIK3CA, CTNNB1, CDKN2A, NFE2L2, as shown in Table 1. The probe sequences are shown in Table 2. Each probe is 120bp in length, and the 5' end of the probe is labeled with biotin.
[0040] The probe group disclosed in the present invention can achieve good coverage and capture of the target area, obtain sufficient read information on the target area, and thus play a role in monitoring tumor evolution and emerging drug-resistant mutations, while also stabilizing the experimental system and improving capture efficiency.
[0041] Those skilled in the art will appreciate that the probe set disclosed herein can be used alone or in combination with any other conventional probe set.
[0042] In some embodiments, the probe group of the present disclosure can be used in combination with a patient-personalized probe group for detecting MRD, such as the personalized probe group for MRD detection described in Chinese patent document No. 202310890251.0.
[0043] The probe set provided by the present disclosure can accurately detect mutations related to small residual lesions of non-small cell lung cancer, has good sensitivity and specificity, and has good application prospects in MRD monitoring of non-small cell lung cancer.
[0044] definition
[0045] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.
[0046] As used herein, the articles "a," "an," and "an" include plural referents unless the context clearly dictates otherwise.
[0047] The expression "about" as used herein is understood by one of ordinary skill in the art and varies within a certain range depending on the context in which it is used. If one of ordinary skill in the art is not aware of the use of the term based on the context in which it is used, "about" will mean up to plus or minus 10% of the specified value.
[0048] In this application, the term "lung cancer" has its general meaning in the art and refers to a disease involving uncontrolled cell growth in lung tissue, which may lead to metastasis in some cases. Most primary lung cancers are lung cancers derived from epithelial cells. In some embodiments, lung cancer may be stratified into any of the aforementioned stages (e.g., latent, 0 phase, IA phase, IB phase, IIA phase, IIB phase, IIIA phase, IIIB phase, or IV phase). The main types of lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In a specific embodiment, the subject suffers from non-small cell lung cancer. The term "non-small cell lung cancer" as used herein, also referred to as non-small cell lung cancer (NSCLC), refers to epithelial lung cancer except small cell lung cancer (SCLC). There are mainly three subtypes: adenocarcinoma, squamous cell carcinoma of the lung, and large cell lung cancer. Other less common types of non-small cell lung cancer include polymorphism, carcinoid, salivary gland carcinoma, and unclassified cancer.
[0049] In this application, the term "MRD" may be an abbreviation of three terms, namely, molecular residual disease, measurable residual disease, and minimal residual disease. MRD reflects the residual status of tumor lesions. After treatment, a small amount of tumor cells may remain in the body of the tumor subject, and the number of these tumor cells may be so small that they do not cause any symptoms or signs. They are usually not detected by traditional means such as cytological microscopy or serological examinations. Detection requires the use of highly sensitive modern cutting-edge technologies such as flow cytometry, PCR, NGS, etc.
[0050] In the present application, the term "cfDNA" refers to circulating free DNA, including DNA molecules naturally present in an extracellular form in a subject (e.g., in blood, serum, plasma, or other body fluids such as lymph, cerebrospinal fluid, urine, or sputum). Although cfDNA is initially present in one or more cells in a large complex biological organism (e.g., mammal), cfDNA undergoes release from the cells into the fluid present in the organism and can therefore be obtained by obtaining a sample of the fluid without the need for an in vitro cell lysis step.
[0051] In this application, the term "ctDNA" refers to circulating tumor DNA (ctDNA), which is a DNA fragment derived from apoptosis, necrosis or secretion of tumor cells, and contains the same genetic variation and epigenetic modification as tumor tissue DNA, such as point mutation, gene rearrangement, fusion, copy number variation, methylation modification, etc. The detection of ctDNA can be applied to early cancer screening, diagnosis and staging, guidance of targeted drug use, efficacy evaluation, recurrence monitoring and other aspects. Combining the information of tumor-specific gene variation and methylation carried by ctDNA can help improve the sensitivity and specificity of detection, detect cancer traces earlier, and is of great significance for early cancer screening.
[0052] In this application, the term "gene marker" refers to a molecular indicator having a specific biological property, biochemical characteristic or aspect, which can be used to determine the presence or absence and / or the severity of a specific disease or condition.
[0053] In this application, the term "marker" refers to a parameter associated with one or more biological molecules (ie, a "genetic marker"), such as a nucleic acid produced naturally or artificially.
[0054] In this application, the term "sequence identity" refers to the "percentage of sequence identity" or "percentage of sequence identity" between two polynucleotides, i.e., the number of identical matching positions shared by the sequences within a comparison window, taking into account additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences. A matching position is any position where the same nucleotide is present in both the target sequence and the reference sequence. Since a gap is not a nucleotide, a gap present in the target sequence is not counted. Likewise, since the target sequence nucleotides are counted and the nucleotides from the reference sequence are not counted, the gaps present in the reference sequence are not counted. At least 60% sequence identity includes a contiguous segment having at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity over the entire length of the sequence.
[0055] The sequence identity percentage can be calculated by the following process: determine the number of positions where the same amino acid residue or nucleic acid base occurs in both sequences to obtain the number of matching positions, divide the number of matching positions by the total number of positions in the comparison window, and multiply the result by 100 to obtain the sequence identity percentage. The determination of the sequence identity percentage between the comparison of the sequence and the two sequences can be completed using software that is easy to use and download online. Suitable software programs can be obtained from various sources for the comparison of protein and nucleotide sequences. A suitable program for determining the sequence identity percentage is bl2seq, which is a part of the BLAST program suite that can be obtained from the BLAST website (blast.ncbi.nlm.nih.gov) of the National Center for Biotechnology Information of the U.S. Government. Bl2seq uses BLASTN or BLASTP algorithms to compare between two sequences. BLASTN is used for comparing nucleic acid sequences, and BLASTP is used for comparing amino acid sequences. Other suitable programs are, for example, Needle, Stretcher, Water or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk / Tools / psa.
[0056] In this application, the term "CSCO guidelines" refers to various clinical practice guidelines for malignant tumors issued by the Chinese Society of Clinical Oncology.
[0057] In this application, the term "TCGA database" refers to the Cancer Genome Atlas Program, which currently contains data from 20,000 patients and 33 types of cancer. It includes genome, transcriptome, epigenetic, proteome and other omics data, as well as clinical sample information.
[0058] In this application, the term “Cosmic Database” refers to the Catalog of Cancer Somatic Mutations, which is a comprehensive database that details driver genes associated with human cancer.
[0059] As used herein, the term "sequencing" refers to the process of determining the sequence (eg, the identity and order of monomeric units) of a biological molecule, eg, a nucleic acid, such as DNA or RNA. Exemplary sequencing methods include, but are not limited to, targeted sequencing, single molecule real-time sequencing, exon or exome sequencing, intron sequencing, electron microscopy-based sequencing, panel sequencing, transistor-mediated sequencing, direct sequencing, random shotgun sequencing, Sanger dideoxy terminator sequencing, whole genome sequencing, hybridization sequencing, pyrosequencing, capillary electrophoresis, duplex sequencing, cycle sequencing, single base extension sequencing, solid phase sequencing, high-throughput sequencing, massively parallel signature sequencing, emulsion PCR, low denaturation temperature co-amplification PCR (COLD-PCR), multiplex PCR, reversible dye terminator sequencing, paired end sequencing, near-term sequencing, exonuclease sequencing, ligation sequencing, short read sequencing, single molecule sequencing, sequencing by synthesis, real-time sequencing, reverse terminator sequencing, nanopore sequencing, 454 sequencing, Solexa Genome Analyzer sequencing, SOLiD™ sequencing, MS-PET sequencing, DNA nanoball sequencing (DNBSEQ), composite probe anchor polymerase sequencing (cPAS), and combinations thereof. In some embodiments, sequencing can be performed by a genetic analyzer, such as a genetic analyzer commercially available from Illumina, Inc., Pacific Biosciences, Inc., Applied Biosystems / Thermo Fisher Scientific, or Shenzhen MGI Intelligent Manufacturing Technology Co., Ltd., etc. For example, BGI DNBseq sequencing platforms such as BGISEQ-500, BGISEQ-50, MGISEQ-2000, MGISEQ-200, DNBSEQ-T7, DNBSEQ-G99, DNBSEQ-T20X2, or Illumina's HiSeq2000, HiSeq2500, HiSeq4000, HiSeqX10, NovaSeq6000, etc.
[0060] As used herein, the term "computer-readable medium" (e.g., data storage, data storage, etc.) or "computer-readable storage medium" refers to any medium that participates in providing instructions to a processor for execution. Such media can take many forms, including but not limited to non-volatile media, volatile media, and transmission media. Examples of non-volatile media can include but are not limited to optical disks, solid-state disks, magnetic disks, such as storage devices. Examples of volatile media can include but are not limited to dynamic memory, such as memory.
[0061] Common forms of computer readable media include, for example, floppy disks, diskettes, hard disks, magnetic tape or any other magnetic medium, CD-ROMs, any other optical medium, punch cards, paper tape, any other physical medium with patterns of holes, RAM, PROM and EPROM, FLASH-EPROM, any other memory chip or cassette, or any other tangible medium from which a computer can read.
[0062] In addition to computer-readable media, data can be provided as a signal on a transmission medium included in a communication device or system to provide one or more instruction sequences to a processor of a computer system for execution. For example, a communication device may include a transceiver with a signal indicating instructions and data. The instructions and data are configured to cause one or more processors to implement the functions outlined in this disclosure. Representative examples of data communication transmission connections may include, for example, telephone modem connections, wide area networks (WANs), local area networks (LANs), infrared data connections, NFC connections, etc.
[0063] Examples and drawings are provided below to help understand the present invention. However, it should be understood that these examples and drawings are only used to illustrate the present invention, but do not constitute any limitation. The actual protection scope of the present invention is set forth in the claims. It should be noted that for those skilled in the art, several variations and improvements made on the basis of this invention and creation concept all belong to the protection scope of the present invention. In the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concepts of the present disclosure. Such structures and technologies are also described in many publications. The equipment, instruments, reagents and / or kits used in the following examples are not mentioned in terms of their sources, and are all commercially available on the market, or obtained by conventional methods known to those skilled in the art.
[0064] Example
[0065] Example 1: Target and probe combination screening for non-small cell lung cancer
[0066] In order to screen the drug targets and high-frequency mutation sites of non-small cell lung cancer, the drug targets provided by the database and the sequencing data of 12,854 patients with non-small cell lung cancer were analyzed and calculated to screen out the drug target regions and high-frequency mutation regions related to non-small cell lung cancer, as shown in Table 1.
[0067] Table 1. Non-small cell lung cancer marker combination
[0068]
[0069]
[0070] Based on the above non-small cell lung cancer drug mutations and high-frequency mutation regions, a cancer-specific probe set was designed, and the probe sequences are shown in Table 2.
[0071] Table 2. Non-small cell lung cancer specific MRD probe set
[0072]
[0073]
[0074]
[0075]
[0076] Example 2: Evaluation of capture efficiency and uniformity of non-small cell lung cancer specific probes for clinical samples
[0077] The performance of the NSCLC-specific probe was tested using cfDNA samples from clinical patients with NSCLC to evaluate the capture efficiency and uniformity of the probe.
[0078] (1) Test process:
[0079] ①cfDNA extraction: Whole blood samples were centrifuged at 1,600g and 16,000g to separate plasma and remove cell debris in plasma. TM The plasma cfDNA was extracted using the magnetic bead method using the Cell-free DNA Isolation Kit (Thermo Fisher).
[0080] ②Library construction: The cfDNA was end-repaired and "A" was added using a customized detection kit for human molecular residual disease (MRD) (Gene Plus), and then the pre-capture intermediate library was obtained through the process of adapter connection, purification, pre-capture PCR (Non-C-PCR) and purification. The samples with qualified concentration quality control of the intermediate library were subsequently subjected to hybridization elution.
[0081] ③ Hybridization capture: The library that passed the concentration quality control was pooled, evaporated, hybridized with mixed probes, eluted, PCR of the eluted products, and purified using the customized detection kit for human molecular residual disease (MRD) (Gene Plus) to obtain the common library after hybridization. The common library was sequenced after passing the concentration and fragment distribution quality control.
[0082] ④ Sequencing and FASTQ data output: Double-end (PE100) sequencing was performed using the Gene+Seq2000 sequencer, and the data was split into fastq files after being downloaded.
[0083] ⑤ Data alignment and bam file generation: Before data alignment, Realseq2 software (version: 1.1.6) was first used to: (1) remove the UMI at the end of the read and save it in the read name; (2) filter low-quality reads. The obtained fastq was aligned to the human reference genome (version: hs37d5) using BWA (version: 0.7.15-r1140) software to generate the bam file of the initial alignment result. Subsequently, Realseq2 software (version: 201808) was used to cluster and correct the PCR duplicate reads in the initial alignment result file with the help of UMI. The indel regions within the 50 bp range at both ends of the detection chip were re-aligned based on the common indel mutations in the 1000 database and dbSNP (version: 138) database. The base quality values within the 50 bp range at both ends of the detection chip were re-corrected based on the information in the 1000 database, dbSNP (version: 138) database, and COSMIC database.
[0084] ⑥Sample quality control: (1) Sample pairing error: The bioinformatics process determines the sample pairing by calculating the consistency of the homozygous sites in the control sample within the range of 50 bp extending from both ends of the chip interval and the tumor sample. (2) Sample contamination: The Calculate Contamination module in the GATK (version: 4.1.4) software combines the bam file information of the control and tumor samples, and reads and counts the reads information supporting the reference base in the homozygous sites in the test sample to evaluate the cross-contamination of the sample.
[0085] ⑦ Mutation calling: This product detects single nucleotide mutations (SNVs) and insertion / deletion mutations (Indels), as well as SVs, within a range of 50 bp extending from both ends of the chip capture interval. The mutations obtained in the above detection process are annotated using the following databases: (1) Gene Annotation Database (version: NCBI release 104); (2) dbSNP Database (version: 147); (3) tgp Database (version: phase3); (4) COSMIC Database (version: v80); (5) ExAC Database (version: 0.3.1); (6) clinvar Database (version: 20200701). The mutations obtained in the above steps are filtered and credible mutations are retained.
[0086] In this embodiment, cfDNA samples from 10 clinical patients with non-small cell lung cancer were used to test the probe capture efficiency, uniformity and probe depth coefficient. The probe used in step ③ hybridization capture is a personalized probe set for detecting non-small cell lung cancer (the nucleotide sequence of the personalized probe is shown in SEQ ID NO: 58-79 listed in Table 3, hereinafter referred to as the non-small cell lung cancer personalized probe set) used alone, or a non-small cell lung cancer specific probe set provided in this application (the nucleotide sequence of the probe is shown in SEQ ID NO: 1-57 listed in Table 2, hereinafter referred to as the non-small cell lung cancer specific probe set) used alone, or both are used in combination.
[0087] Table 3. Nucleotide sequences of personalized probe sets for detecting non-small cell lung cancer
[0088]
[0089]
[0090] (2) Probe capture efficiency
[0091] The probe capture efficiency test results of clinical samples are as follows Figure 1 As shown. The results showed that the capture efficiency of the personalized probe set for non-small cell lung cancer ranged from 24.5% to 37.0%, with a median capture efficiency of 32.8%, the capture efficiency of the non-small cell lung cancer specific probe set ranged from 48.7% to 57.6%, with a median capture efficiency of 52.5%, and the capture efficiency of the superposition of the personalized probe set for non-small cell lung cancer and the non-small cell lung cancer specific probe set ranged from 50.8% to 58.7%, with a median capture efficiency of 53.8%. The above results show that compared with the use of only the personalized probe set for non-small cell lung cancer, the capture efficiency of the non-small cell lung cancer specific probe set is significantly increased, and the superposition of the personalized probe set for non-small cell lung cancer and the non-small cell lung cancer specific probe set can significantly improve the capture efficiency.
[0092] (3) Probe uniformity
[0093] The results of the probe uniformity test using the non-small cell lung cancer specific probe set alone are as follows Figure 2 and Figure 3 The results are shown in Figure 2 As shown in Figure 2, the percentage of probes with a depth ≥ 0.2 times the average depth in all 10 cfDNA samples was 100%. Figure 3 As shown in the figure, among the 10 cfDNA samples, the percentage of probes with a depth ≥ 0.5 times the average depth was 98.7% at the minimum, 99.7% at the maximum, and 99.3% at the median. The above results show that the uniformity of the non-small cell lung cancer specific probe set is excellent and meets the needs of clinical testing.
[0094] (4) Probe depth factor
[0095] The depth coefficient results of the non-small cell lung cancer specific probe set are as follows Figure 4 The test results show that the median value of the probe depth coefficient of the 10 samples is between 1.00 and 1.04, indicating that the non-small cell lung cancer specific probe set has a relatively consistent depth and the depth coefficient is stable in different samples.
[0096] Example 3: Accuracy of non-small cell lung cancer specific probe set for detecting MRD status of non-small cell lung cancer
[0097] 19 clinical NSCLC patients were included to confirm the accuracy of NSCLC-specific probes in detecting MRD status. First, comprehensive genomic analysis was performed on FFPE samples of 19 patients to identify the mutation profile of each patient. Then, 2-20 mutations were screened out based on the mutation profile to design patient-specific personalized probes. The sequences of the patient-specific personalized probes are shown in Table 4 and are superimposed with the NSCLC-specific probe set for MRD detection of postoperative blood. Patients were followed up every 3-6 months after surgery, and 20 mL of peripheral blood was collected for MRD detection. A total of 40 cfDNA samples from 19 clinical NSCLC patients were tested.
[0098] Table 4. Personalized probes customized for 19 clinical patients with non-small cell lung cancer
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107] Note: If the mutation detected in the tissue is covered by the non-small cell lung cancer specific probe set, personalized probes are no longer required for MRD monitoring.
[0108] First, we evaluated the coverage of NSCLC-specific probe sets for mutations detected in tissues from 19 patients. Figure 5As shown, 100% of tissue samples can be covered by at least one mutation by the non-small cell lung cancer specific probe set, and each sample covers a median of 2 mutations, indicating that the non-small cell lung cancer specific probe set has good coverage for non-small cell lung cancer patients.
[0109] Then, the accuracy of NSCLC-specific probe sets and personalized probe sets in detecting the MRD status of NSCLC was evaluated. Imaging confirmed that 9 of the 19 patients had relapsed and 10 had not. Figure 6 As shown, 8 of the 9 patients who relapsed were identified as MRD positive, with a sensitivity of 89% (8 / 9), and all 10 patients who did not relapse were identified as MRD negative, with a specificity of 100% (10 / 10), indicating that the non-small cell lung cancer cancer-specific probe set provided by the present invention has high accuracy for non-small cell lung cancer MRD monitoring. In addition, among the 8 patients who relapsed and were MRD positive, the mutations detected in 9 plasma samples of 6 patients were covered by the non-small cell lung cancer cancer-specific probe set, and the detected mutations are shown in Table 5, with a patient coverage rate of 75% (6 / 8), indicating that the non-small cell lung cancer cancer-specific probe set has a high coverage rate for non-small cell lung cancer MRD-positive patients.
[0110] Table 5. Coverage results of 19 non-small cell lung cancer specific probe sets for MRD-positive patients
[0111]
[0112] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. All technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.
Claims
1. A gene marker for detecting minimal residual lesions of non-small cell lung cancer, characterized in that: The markers include any one or more of the following genes: EGFR, KRAS, ERBB2, BRAF, MET, ALK, TP53, PIK3CA, CTNNB1, SMAD4, CDKN2A or NFE2L2.
2. The gene marker according to claim 1, characterized in that The gene markers cover at least any one or more of the following regions: exons 18, 19, 20, and 21 of EGFR; exons 2, 3, and 4 of KRAS; exon 20 of ERBB2; exons 11 and 15 of BRAF; intron 13 and exon 14 of MET; exon 23 of ALK; exons 4-10 of TP53; exons 10 and 21 of PIK3CA; exon 3 of CTNNB1; exon 9 of SMAD4; exons 1 and 2 of CDKN2A and exon 2 of NFE2L2.
3. A probe set for detecting microresidual lesions of non-small cell lung cancer, characterized in that: The probe set is used to detect the gene marker according to claim 1 or 2.
4. The probe set according to claim 3, characterized in that: The probe set has a nucleotide sequence as shown in any one or more of SEQ ID NOs: 1 to 57, or a nucleotide sequence having at least 85% sequence identity therewith.
5. The probe set according to claim 3, characterized in that: The probe set includes any one or more combinations of the following: A probe for detecting the ALK gene: having a nucleotide sequence as shown in SEQ ID NO: 1 and / or 2, or a nucleotide sequence having at least 85% sequence identity thereto; and / or A probe for detecting the NFE2L2 gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 3 to 5, or a nucleotide sequence having at least 85% sequence identity thereto; and / or A probe for detecting the CTNNB1 gene: having a nucleotide sequence as shown in SEQ ID NO: 6 and / or 7, or a nucleotide sequence having at least 85% sequence identity thereto; and / or A probe for detecting the PIK3CA gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 8 to 12, or a nucleotide sequence having at least 85% sequence identity thereto; and / or A probe for detecting the EGFR gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 13 to 20, or a nucleotide sequence having at least 85% sequence identity thereto; and / or A probe for detecting the MET gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 21 to 23, or a nucleotide sequence having at least 85% sequence identity thereto; and / or A probe for detecting the BRAF gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 24 to 27, or a nucleotide sequence having at least 85% sequence identity thereto; and / or A probe for detecting the CDKN2A gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 28 to 32, or a nucleotide sequence having at least 85% sequence identity thereto; and / or A probe for detecting the KRAS gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 33 to 38, or a nucleotide sequence having at least 85% sequence identity thereto; and / or A probe for detecting the TP53 gene: having a nucleotide sequence as shown in any one or more of SEQ ID NOs: 39 to 53, or a nucleotide sequence having at least 85% sequence identity thereto; and / or A probe for detecting the ERBB2 gene: having a nucleotide sequence as shown in SEQ ID NO: 54 and / or 55, or a nucleotide sequence having at least 85% sequence identity thereto; and / or The probe for detecting the SMAD4 gene has a nucleotide sequence as shown in SEQ ID NO: 56 and / or 57, or a nucleotide sequence having at least 85% sequence identity thereto.
6. A kit for detecting minimal residual lesions of non-small cell lung cancer, characterized in that: The kit comprises the probe set according to any one of claims 3 to 5.
7. A method for detecting minimal residual lesions of non-small cell lung cancer using the probe set according to any one of claims 3 to 5 and / or the kit according to claim 6, the method comprising using the probe set and / or the kit to detect minimal residual lesions of non-small cell lung cancer.
8. Use of the gene marker according to claim 1 or 2 and the probe group according to claims 3 to 5 in preparing a kit for detecting minimal residual lesions of non-small cell lung cancer.
9. The use according to claim 8, characterized in that: The kit is used for detecting cell, tissue or body fluid samples.
10. The use according to claim 9, characterized in that: The body fluid samples include: saliva, whole blood, serum, plasma, milk, urine, lumbar or ventricular CSF, bile, lymph, prostatic fluid, semen, sputum, feces, tears, tumor cells, alveolar lavage fluid, sputum, pus, nasopharyngeal swab, oral swab, cerebrospinal fluid, pleural effusion, amniotic fluid, peritoneal fluid, aqueous humor, vitreous humor, vaginal discharge and their processed products; and / or, The tissue samples include lung cancer tissues, paraffin sections and processed materials thereof.
Citation Information
Patent Citations
Building method of library for detecting non-small cell lung cancer gene mutation and kit
CN106497920A
Application of gene marker in prognosis evaluation of non-small cell lung cancer, detection device and computer readable medium
CN116287233A
Design method and application of cancer species specific core probe group for MRD detection
CN117144003A
Capture probe pool and kit for lung cancer MRD detection
CN117721202A
Combination panel cell-free DNA monitoring
WO2024097257A1
Cited By
Probe group for judging systemic tumor load of triple-negative breast cancer and application of probe group
CN119799891A
